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They include the technical performance of the operation,
perioperative antiplatelet and anticoagulant medication,
patient selection, and statistical aberrancy. Two surgeons
performed the operations, and their results were similar,
although the numbers are small in these subselected
groups. Not all patients received preoperative antiplatelet
therapy, but the proportion of patients receiving preopera-
tive antiplatelet therapy was similar in the patients with and
without stroke or occlusion (71% vs 66%). The randomiza-
tion process as described is adequate, and the demographic
comparison of the groups is not statistically different, but
the patients randomized to the Hemashield-treated group
were twice as likely to have had a preoperative stroke than
those randomized to the PTFE-treated group. The study
was powered to give an 80% power of detecting a differ-
ence between groups at the 95% confidence level with 88
patients per group. Although this number was met and
even exceeded, it is a very small number of patients per
group, particularly for a study of carotid endarterectomy.
Thus even a small difference in demographics (such as an
increased number of patients with symptoms in one group)
or outcomes between groups could have a significant effect
on the study conclusions.
The finding of a 5% acute carotid artery occlusion rate
after carotid endarterectomy is quite unusual. To me, a 5%
acute occlusion rate is clinically unacceptable, and if it were
occurring in my practice, my hospital, or my community, I
would be aware of it and aggressively trying to identify the
causes. My practice group has performed more than 1000
carotid endarterectomies in the last 10 years. More than
500 of these were closed with Hemashield patching with
an acute carotid artery occlusion rate of <1%. I am not
aware of an acute occlusion rate in my vascular surgical
community of the magnitude reported in this article, in
spite of the widespread use of the Hemashield patch. Nor
I am aware of any other report in the literature with an
incidence of acute carotid artery occlusion at this level.
Thus I believe that the conclusion that Hemashield
patches are thrombogenic in the carotid artery position is
In this issue of the Journal of Vascular Surgery,
AbuRahma et al1 report their results of a randomized
series of carotid endarterectomies in which collagen-
impregnated Dacron patches (Hemashield, Boston
Scientific, Natick, Mass) and polytetrafluoroethylene
(PTFE) were compared. The end point used was a combi-
nation of perioperative stroke, carotid artery occlusion,
and restenosis (≥50%). The authors postulated a combined
end point of 26% in the Hemashield-treated group versus
3% in the PTFE-treated group on the basis of the results
they found in a prior study.2 They concluded from their
data that Hemashield patching yielded significantly poorer
outcomes when compared with PTFE and theorized that
this is due to thrombogenicity of the Hemashield patch
when it is placed in the carotid artery position. Specifically,
with 100 endarterectomies in each group, they had five
carotid artery occlusions with Hemashield patching versus
zero with PTFE (P = .07), five transient ischemic attacks
with Hemashield versus three with PTFE (P = .718),
seven strokes with Hemashield versus zero with PTFE (P
= .02), and seven ≥50% restenoses with Hemashield versus
two with PTFE. It is important to note that all five of the
patients with carotid artery occlusion also had strokes. The
combined end points of stroke, perioperative occlusion,
and ≥50% restenosis are not stated in the article, but they
are 14% with Hemashield versus 2% with PTFE.
Other reasons could explain the data presented besides
the authors’ postulation of increased thrombogenicity of
the Hemashield material in the carotid artery position.
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premature. The statistical significance of the results may be
based on aberrancies in randomization and outcomes that
are magnified as a result of the small group size.
Obviously, my conclusion could be wrong, and the find-
ing reported in this study merits further study. This type
of report reinforces the need to honor the request of the
Food and Drug Administration that adverse drug and
device event reports be submitted in a timely fashion. If
the vascular community reported all acute carotid artery
occlusions that occurred after carotid endarterectomy and
prosthetic patching, we would rapidly know whether there
was an epidemic of acute occlusions. I suspect that this is
not what we will find.
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